| 张腾腾,顾康生.GLD与CHOP方案一线治疗外周T细胞淋巴瘤的疗效分析[J].安徽医药,2016,20(2):287-290. |
| GLD与CHOP方案一线治疗外周T细胞淋巴瘤的疗效分析 |
| Effect of GLD and CHOP first-line chemotherapy for peripheral T-cell lymphoma |
| 投稿时间：2015-10-09 |
| DOI： |
| 中文关键词: 外周T细胞淋巴瘤 CHOP方案 GLD方案 |
| 英文关键词: peripheral T-cell lymphoma CHOP regimen GLD regimen |
| 基金项目: |
|
| 摘要点击次数: 2847 |
| 全文下载次数: 87 |
| 中文摘要: |
| 目的 探讨GLD(吉西他滨+奥沙利铂+地塞米松)与CHOP(环磷酰胺+多柔比星/表柔比星+长春新碱+泼尼松)方案一线治疗外周T细胞淋巴瘤的疗效与安全性。方法 回顾性分析2010年1月—2015年4月诊治的外周T细胞淋巴瘤患者35例。17例采用GLD方案,18例采用CHOP方案。对比两组的疗效与不良反应。结果 GLD组与CHOP组客观有效率(ORR)分别为64.7%和50.0%,差异无统计学意义(P>0.05)。但NK/T细胞淋巴瘤亚型的ORR分别为100%和50%,差异有统计学意义(P<0.05)。GLD组与CHOP组中位无进展生存期(PFS)(12月 vs 4月)及2年生存率(73.2% vs 36.1%)的差异均有统计学意义(P<0.05)。两组不良反应主要为骨髓抑制,差异无统计学意义(P>0.05)。 结论 GLD方案治疗外周T细胞淋巴瘤近期疗效与CHOP方案相似(NK/T细胞亚型疗效优于CHOP方案),远期疗效优于CHOP方案,不良反应可耐受,是值得推广的一线治疗方案。 |
| 英文摘要: |
| Objective To investigate the efficacy and safety of GLD(gemcitabine + oxaliplatin+ dexamethasone) and CHOP(cyclophosphamide+ doxorubicin/epirubicin+ vincristine+ prednisone ) first-line chemotherapy for peripheral T-cell lymphoma.Methods From January 2010 to April 2015,thirty-five patients with peripheral T-cell lymphoma were enrolled in the study.Seventeen patients received the GLD regimen and eighteen received the CHOP regimen.The curative effect and adverse reactions between two groups were compared.Results The objective response rate (ORR) for GLD versus CHOP was 64.7% versus 50.0%,showing no statistically significant difference (P > 0.05).However,ORR were 100% and 50% respectively for NK/T cell lymphoma subtypes with statistically significant difference (P<0.05).Between GLD and CHOP,the median progression-free survival (PFS) (12 months vs 4 months) and 2-year survival rate (73.2% vs 36.1%) were statistically significant (P<0.05).The major adverse reaction was myelosuppression in both groups,but with no statistically significant difference (P>0.05).Conclusions The short-term curative effect of GLD first-line chemotherapy for peripheral T-cell lymphoma is similar to CHOP (curative effect of NK/T cell subtype is superior to CHOP).The long-term curative effect is superior to the CHOP and adverse reaction is tolerable.GLD is recommendable as first-line chemotherapy for PTCL. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
